T. E. Witzig
Impact in
- Toxicology top 2%
- Bioactive Compounds and Antitumor Agents
- Oncology top 10%
- Inflammatory Biomarkers in Disease Prognosis
- Cancer-related Molecular Pathways
Papers in
-
- Lymphoma Diagnosis and Treatment 5
- Oncology 5
- Cancer-related Molecular Pathways 2
- Cancer Immunotherapy and Biomarkers 2
- Co-authors
- Alex A. Adjei (1 shared paper)Irene M. Ghobrial (1 shared paper)Thomas M. Habermann (2 shared papers)Kay M. Ristow (1 shared paper)Joseph P. Colgan (1 shared paper)S. N. Markovic (1 shared paper)G. S. Nowakowski (1 shared paper)Steven M. Ansell (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)European Journal Of Haematology (1 paper)CA A Cancer Journal for Clinicians (1 paper)HemaSphere (1 paper)Haematologica (1 paper)
- Partner nations
- United StatesGermanyItaly
In The Last Decade
T. E. Witzig
12 papers receiving 1.5k citations
T. E. Witzig's Hit Papers
Peers
Comparison fields: 5 of 100
- Toxicology 75
- Oncology 384
- Cancer Research 165
- Molecular Biology 816
- Pathology and Forensic Medicine 186
Countries citing papers authored by T. E. Witzig
This map shows the geographic impact of T. E. Witzig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. E. Witzig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. E. Witzig more than expected).
Fields of papers citing papers by T. E. Witzig
This network shows the impact of papers produced by T. E. Witzig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. E. Witzig. The network helps show where T. E. Witzig may publish in the future.
Co-authors
The 25 scholars most cited alongside T. E. Witzig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Targeting Apoptosis Pathways in Cancer Therapy Hit paper breakdown → | 2005 | 1175 |
| 2 | 2011 | 166 | |
| 3 | 2009 | 92 | |
| 4 | Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. | 2000 | 43 |
| 5 | 2016 | 36 | |
| 6 | 1991 | 27 | |
| 7 | 1996 | 12 | |
| 8 | 2003 | 12 | |
| 9 | Zevalin radioimmunotherapy is not associated with significant or prolonged depletion of t cells or natural killer cells | 2000 | 3 |
| 10 | 2019 | 1 | |
| 11 | 2009 | 1 | |
| 12 | 2004 | 1 | |
| 13 | 2006 | 1 |
About T. E. Witzig
T. E. Witzig is a scholar working on Pathology and Forensic Medicine, Oncology, Molecular Biology, Genetics and Hematology, having authored 13 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (5 papers), Chronic Lymphocytic Leukemia Research (3 papers), Cell death mechanisms and regulation (2 papers), Cancer-related Molecular Pathways (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Lung Cancer Treatments and Mutations (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Chronic Myeloid Leukemia Treatments (1 paper). The work is most often cited by research in Toxicology (75 citations), Oncology (384 citations), Cancer Research (165 citations), Molecular Biology (816 citations) and Pathology and Forensic Medicine (186 citations). T. E. Witzig has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Alex A. Adjei, Irene M. Ghobrial, Thomas M. Habermann, Kay M. Ristow, Joseph P. Colgan, S. N. Markovic, G. S. Nowakowski, Steven M. Ansell, Luis F. Porrata and Ivana N. Micallef. Their work appears in journals such as Journal of Clinical Oncology, European Journal Of Haematology, CA A Cancer Journal for Clinicians, HemaSphere and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.